Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), a China-based pharmaceutical company, has announced that it has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for its Category 1 chemical drug, NH300231, which is intended for the treatment of schizophrenia. This next-generation atypical antipsychotic drug is characterized as a 5-HT2A receptor antagonist and a dopamine receptor modulator, with a notably higher antagonistic activity against 5-HT2A receptors compared to dopamine D2 receptors. Additionally, it exhibits inhibitory effects on the activity of serotonin transporters. Pre-clinical studies have demonstrated the drug’s efficacy across multiple animal models of schizophrenia.- Fineline.com
Recent news:
-
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA -
Sihuan Pharmaceutical's Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China -
Innovent Biologics' IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment -
CDE Includes Double-Crane's Hydroxocobalamine and Sanofi Genzyme's Fitusiran in Rare Disease Care Plan -
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
